Stroke-Associated Pneumonia: Risk Factors, Mechanisms, and Interventions
Stroke-associated pneumonia research over the past 2 decades has yielded significant insight into SAP risk factors, diagnostic measures, and management strategies.
Stroke-associated pneumonia research over the past 2 decades has yielded significant insight into SAP risk factors, diagnostic measures, and management strategies.
Presenting at the 2022 AAN Annual Meeting, researchers explored the association between β2-adrenoreceptor agonists and the risk for Parkinson disease.
In a global, phase 3 trial, researchers evaluated the efficacy of ganaxolone as an adjunctive treatment compared to placebo for major motor seizures in patients with CDKL5 deficiency disorder.
Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.
Presenting at the 2022 AAN Annual Meeting, Mayo Clinic researchers investigated and compared the survival rates and symptoms of Parkinson disease and Parkinson disease psychosis.
Researchers assessed the efficacy of a natalizumab 6-week dosing schedule in patients with multiple sclerosis who received natalizumab 4-week dosing without relapse for 12 or more months.
Presenting at the 2022 AAN Annual Meeting, the researchers hypothesized that low LDL levels may be linked to severe ICH at presentation and worse outcomes.
In a systematic review and meta-analysis of longitudinal studies, researchers used neuroimaging for its predictive ability to determine cognitive decline and disability outcomes in MS.
Researchers sought to assess the loss of insight related to behavioral changes across cognitive profiles in amyotrophic lateral sclerosis subgroups.
Using Mendelian randomization, researchers investigated which cardiovascular risk factors are likely to be implicated in the etiology of cerebral small vessel disease.